The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: A case study with fexofenadine hydrochloride

Biopharmaceutics and Drug Disposition

Volumn 25, Issue 9, 2004, Pages 373-387

  Krishna, Rajesh ^a,b   Krishnaswami, Sriram ^a,c   Kittner, Barbara ^a   Sankoh, Abdul J ^a   Jensen, Bradford K ^a  

^a SANOFI   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

^c PFIZER INC   (United States)

Author keywords

Allergic rhinitis; Fexofenadine hydrochloride; NONMEM; Pediatric population; Pharmacokinetics; Simulation

Indexed keywords

ANTIHISTAMINIC AGENT; FEXOFENADINE;

AGE DISTRIBUTION; ALLERGIC RHINITIS; ANALYTICAL ERROR; ARTICLE; BODY WEIGHT; CALCULATION; CHILD; CHRONIC URTICARIA; CLINICAL TRIAL; COMPUTER PROGRAM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EXPOSURE; HUMAN; IDIOPATHIC DISEASE; NORMAL DISTRIBUTION; PEDIATRICS; PHARMACODYNAMICS; SEASONAL VARIATION; SIMULATION; STATISTICAL MODEL; STATISTICAL PARAMETERS;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; ANALYSIS OF VARIANCE; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; INFANT; MALE; MODELS, BIOLOGICAL; RHINITIS, ALLERGIC, SEASONAL; SEX FACTORS; TERFENADINE;

EID: 11144348138     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.425     Document Type: Article

References (16)

1. Markham A, Wagstaff AJ. Fexofenadine. Drugs 1998; 55 269-274.
2. Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000; 59: 301-321.
3. Bernstein DI, Schoenwetter WF, Nathan RA, Storms W, Ahlbrandt R, Mason J. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79: 443-448.
4. Meeves SG, Appajosyula S. Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol 2003; 112(4 Suppl): S69-S77.
5. Wahn U, Meltzer EO, Finn AF Jr, et al. Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis. J Allergy Clin Immunol 2003; 111: 763-769.
6. Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104 927-933.
7. Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther 1998; 64: 612-621.
8. Robbins DK, Castles MA, Pack DJ, Bhargava VO, Weir SJ. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 1998; 19: 455-463.
9. Tinkelman D, Falliers C, Bronsky E, et al. Efficacy and safety of fexofenadine HCl in fall seasonal allergic rhinitis. J Allergy Clin Immunol 1996; 97: 435.
10. Beal SL, Sheiner LB. NONMEM Users Guides - Part I-VIII. NONMEM Project Group. C255, University of California at San Francisco, San Francisco, CA, 1988-1998.
11. Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical pharmacokinetics of analgesia in pediatric patients. Clin Pharmacokinet 1997; 33: 313-327.
12. Nelson Textbook of Pediatrics, Behrman RE, Kliegman RM, Jenson HB (eds), 16th edn. W.B. Saunders Company, 2000. Table 10-2, page 33, Body weight data are from the National Center for Health Statistics (NCHS), Health Resources Administration, Department of Health, Education, and Welfare.
13. Peters HP. Physiological correlates of size. In The Ecological Implications of Body Size, Beck E, Birks HJB, Conner EF (eds). Cambridge University Press: Cambridge, 1983; 48-53.
14. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997; 276: 122-126.
15. West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999; 284: 1677-1679.
16. Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 1986; 75: 1028-1040.